Vagiprost Vaginal Tablets: Induction of Labor & Cervical Softening

Composition:

Each tablet contains Misoprostol 25mcg.

Properties:

Misoprostol is a synthetic prostaglandin E, analogue, is as effective as dinoprostone for preinduction cervical softening with Bishop scores < 4.

Indications:

Vagiprost vaginal tablet is indicated for cervical softening and induction of labor when there are no fetal or maternal contraindications. Misoprostol in large doses could be used for cervical priming before surgical abortion, miscarriage, and for evacuation of the uterus in cases of fetal death or anomaly.

Dosage Administration:

• In primigravid patients with unfavorable features (Bishop score of 4 or less), an initial dose of 50 mcg may be administered vaginally. In other patients, an initial dose of 25 mcg should be administered vaginally. In both groups of patients, a second dose of 25 mcg or 50 mcg may be used after 6 hours following the assessment of cervical status, myometrial contractility, and fetal condition.
• 25 mcg should be used in multigravid patients where uterine activity is insufficient for satisfactory progress of labor (50 mcg may be used where the response to the initial dose has been minimal).
• The maximum dose is 100 mcg in unfavorable primigravid patients or 75 mcg in other patients in cases of labor induction in advanced pregnancies.
• The tablet should be inserted high into the posterior fornix avoiding administration into the cervical canal.
• The patient should be instructed to remain recumbent for at least 30 minutes.

Contra Indications:

Vagiprost vaginal tablets are not recommended in the following:

• For patients in whom oxytocic drugs are generally contraindicated, or where prolonged contraindications of the uterus are considered inappropriate, such as cases with a history of cesarean section or major uterine surgery.

Precautions and Warnings:

• This product is available only to hospitals and clinics with specialized obstetric units and should be only used where 24 hours resident medical cover is provided.
• In labor induction, cephalopelvic proportions should be carefully evaluated before the use of prostaglandin E.
• During use, uterine activity, fetal status, and the progression of cervical dilatation should be monitored to detect possible evidence of undesired responses, e.g., hypertonus sustained uterine contractions or fetal distress. In cases there is a known history of hypertonic uterine contractility or titanic uterine contractions, it is recommended that uterine activity and the state of the fetus should be continuously monitored throughout, the possibility of uterine rupture should be considered where high tone contractions are sustained.

Side Effects:

• As with all prostaglandin-based medications, the most commonly reported events are vomiting, nausea, and diarrhea. Also, hypersensitivity to the drug, uterine rupture, and cardiac arrest.
• Other adverse events reported with prostaglandins in decreasing order of severity are: Pulmonary-amniotic fluid embolism, abruption placenta, stillbirth, neonatal death, uterine hypercontractility or hypertonus, fetal distress, hypertension, bronchospasm, asthma, fever, backache, rash.

Notes:

Box of 1 blister, each blister contains 10 tablets.

Vagiprost is a product manufactured by Adwia Pharmaceuticals Industries. Adwia is a leading Egyptian company founded in 1984 with a mission to bring the latest technologies and the highest available know-how to the market. They are committed to innovation and care and have a proven track record of success. For more information about Adwia Pharmaceuticals Industries, please visit their website or contact them directly.